INVESTOR RELATION NEWS QIII – 2021

By Quốc Huy
21/10/2021 - 14:45
I. MACRO ENVIRONMENT IN QUARTER III OF 2021 AND FORECAST

The Vietnamese economy in Q3 of 2021 has firstly witnessed the recorded minus growth of 6.17%, which is the deepest drop of Gross Domestic Products (GDP) since Vietnam commenced to calculate and report such figures. Services the sector experienced the highest plummet in Q3 with 9.28% while industry and construction decreased by 5.02%. A positive signal among obstacles is agriculture forestry and fishery in Q3 rising by 1.04%.
GDP of 9 months in 2021 only increased 1.42% year over year. Whereas agriculture forestry and fishery went up by 2.74% and accounted for 12.79%; industry and construction grew by 3.57% and made up 38.03% of total GDP. Services was the sector witnessing the heaviest impacts induced by the pandemic when GDP of 9 months declined 0.69% and constituted 40.19%, the rest portion in GDP structure is product tax minus product subsidies holding 8.99%.
In the context of complicated movement of the Covid-19 pandemic, agriculture forestry and fishery is the area that has brought a momentum for the economy, however, the supply chain-production and consumption have been affected by the mobility restrictions.
Services especially retail and tourism have crashed because of the pandemic. The number of international tourists arriving in Vietnam in Sep 2021 fell dramatically by 97% whilst retail selling goods and consumption services reduced by 28.4%.
Nevertheless, import and export turnover of 9 months in 2021 increased by 24.4% and attained USD 483 billion, in which export of goods rose by 18.8% and import soared by 30.5%. The USA is the largest market of Vietnam export in 9 months with the turnover of USD 69.8 billion, which raised 27.6% compared to the previous year, the next position was China with the value of USD 38.5 billion and grew by 18.3%. EU market recorded a turnover of USD 28.8 billion and went up by 11.6%. (Source: General Statistics Office)
Asian Development Bank (ADB) has forecasted the growth of the Vietnamese economy is 3.8% in an outlook published in Sep, this figure is reduced from 5.8% predicted in July. While World Bank (WB) considered that the prospect of the Vietnamese economy in 2021 would be growing by 4.8% in a report disclosed in Sep with the assumptions that the pandemic might be controlled in quarter III and the economy could be resilient in quarter IV, the following years WB anticipated the growth rate of Vietnam is 6.5%-7%. But in Oct, WB has reduced the forecast growth rate of Vietnam to 2-2.5% in 2021. The recovery of the global economy, especially in the main export markets of Vietnam such as the USA and China has been creating a foundation for the Vietnamese economy to make a breakthrough. However, the pandemic is still going on complicatedly, therefore, Vietnam has to adapt to stay vigilantly with Covid-19 and focus on economic resilience.

II. VIETNAM PHARMACEUTICAL INDUSTRY AND FORECAST

The social distancing orders and mobility restrictions in Q3 have hugely impacted the pharmaceutical industry. ETC witnessed stronger impacts than OTC when the residences delayed hospital visits. However, OTC has encountered challenges due to disruptions of production – supply and consumption in Q3-2021.
Vietnam’s pharmaceutical industry is extremely influenced by the global supply chain disruptions, the rapid increase of transportation fees, and faced high risk of rising prices of materials.
In addition, Vietnam’s pharmaceutical industry in 2020 experienced low growth of only 3% (Source: SSI Research report). At the beginning of 2021, Fitch Solutions forecasted Vietnam pharmaceutical industry would develop by 8.7% in this year. But, the 4th outbreak has been slowing down the growth of such an industry in Q3/2021.
Protective measures to stay vigilantly with Covid and the general recovery of the global economy thanks to vaccine strategies would advocate the pharmaceutical industry to catch the momentum of development.
Besides, the high rate of aging population and the appearance of more and more diseases would stimulate the demand for medicines in the next years. Foreign drugs are more favorable in the high-value segment. According to reports of the Department of Customs 2020, Vietnam imported USD 3.3 billion of pharmaceutical products, increasing by 7,4% year over year; the compound annual growth rate for the period from 2018 to 2020 was 9%. Domestic productions met approximately 47% of the aggregate demand of the whole country. Hence, improvement of product quality, technology innovation, and technology transfer is focused on by local enterprises to gradually replace imported products. Nevertheless, the capability of research and development of domestic firms is constrained. Thus, M&A activities could partially support such companies to solve the problems of products and production processes. But such event is going together with the risk of being acquired and controlled by foreign corporations which are affluent in capital and technology,
Furthermore, the issue of materials is anxiety of enterprises whereas the supply chains were disrupted and especially energy crisis makes electricity prices increase in China. Moreover, China is tightening its policies to protect the environment and the flooding situation is threatening some regions of this nation. Therefore, the prices of materials are predicted to go up in the last months of 2021 and this trend would be extended to 2022.

III. IMP STOCK IN QUARTER III 2021

The total volume of IMP transactions in Q3 in 2021 attained 1,524,481 shares, in which 968,800 shares were traded under order matching and the rest 555,681 ones were dealt by put through methods. There were 23,820 shares transacted per day on average. The total amount of IMP transactions in Q3 2021 was only equal to 19% of the figure of Q3 2021. The impacts of social distancing orders together with struggles in business induced by the pandemic could make IMP stock transactions quiet. The number of orders matched and put through shares in Q3/2021 reduced by 85% and 64% respectively year over year. Closing price of IMP in the last round of Sep 2021 was VND 73,000, which declined 6,800/share compared to the last round of June 2021.

IV. IMEXPHARM PERFORMANCE IN QUARTER III 2021
No. Criteria YTD
30 Sep 2021
% Plan 2021 YTD
30 Sep 2020
Growth Rate
I Operating results (VND billion)      
1 Total net revenue and other incomes 885.4 57.9% 893.4 -0.9%
2 Net revenue 870.1 882.4 -1.4%
3 Operating profit 150.9 164.8 -8.4%
4 Profit before tax 155.1 53.4% 167.3 -7.3%
5 Profit after tax 122.5 139.3 -12.1%
II Assets – Resources (VND billion)        
1 Total assets 2,152.6 2,072.2 3.9%
2 Total owners’ equity 1,727.8 1,632.6 5.8%
3 Charter capital 667.1 642.4 3.8%
III Liquidity ratios (time)        
1 Current ratio 3.2 2.3 0.9 time
2 Quick ratio 1.8 1.3 0.5 time
IV Profitability ratios        
1   Profit before tax/net revenue 17.8% 19.0% -1.2%
2 ROS 14.1%   15.8% -1.7%
3 ROE (latest 4 quarters) 11.5% 12.2% -0.7%
4 ROA (latest 4 quarters) 9.1%
5 EPS (adjusted) latest 4 quarter 2,600 2,555 1.8%
6 BV (VND) adjusted 24,806
7 P/E (time) adjusted 28 18 10 time
8 P/B (time) adjusted 2.9 1.9 1 time
Market price on 30 Sep (VND) 73,000 47,100 55%

As foreseen at the beginning of quarter 3 when the pandemic moved complicatedly, total net revenue and other incomes of Imexpharm in the quarter would decrease dramatically. In detail, total net revenue and other incomes in Q3 dropped 11.7%, which is the highest minus figure witnessed in many years. The pandemic induces business and production to stagnate; therefore, sales in Q3 of Imexpharm declined sharply. The higher production costs caused by applying a 3 or 4 on the spot model have led to the plummet of profit before tax at 32.6% in Q3 2021.
In terms of accumulated revenue until the end of Sep 2021, total net revenue and other incomes attained VND 885.4 billion, dropping by 0.9% year over year and meeting 57.9% of the annual plan. In which, net revenue reached VND 870.1 billion, falling by 1.4% compared to the figure of 9 months in 2020. Profit before tax of 9 months was VND 155.7 billion, declining 7.3% year over year and accounting for 53.4% of the annual target.
The cost of goods sold in 9 months of 2021 decreased by 2.4% compared to the amount of the previous year. While administrative expenses were maintained as last year, selling expenses increased 12.3% because of expenditures for selling programs to boost sales before the pandemic outbreak. In addition, the cost of goods sold was expected to decline more rapidly than revenue since the Company focused on key products with high effectiveness; however, expenses to keep productions safe and to follow the model recommended by the local authorities caused an increase in production cost and gross profit could not meet the plan. Hence, the profit fell more quickly than revenue.
Total assets and total owner’s equity increased slightly year over year. The charter capital also rose due to the fact that in quarter 3 of 2020, ESOP shares issued by Imepxharm had not been recorded, so the charter capital at that time has not been adjusted.
Although the pandemic is complicated, the demand for working capital increased, liquidity ratios of Imexpharm are still kept at a safe level and also improved compared to Q3 2020. The quick ratio and current ratio rose by 0.5 and 0.9 times respectively.
Due to a decrease in profit, all profitability ratios dropped year over year. EPS (calculated by the cycle of 365 days, ended in Q3/2021) was VND 2,600, increased marginally 1.8% compared to the figure of last year. Similarly, BV went up about 2%. As closing price of IMP in Q3, 2021 surged by 55% compared to the closing price of Q3 2020, P/E soared by 10 times and P/B increased 1-time year over year.

V. KEY FOCUS IN Q4 2021

In Q4 2021, the top priority of Imexpharm is to keep business and production safe. Currently, Imexpharm is still applying 3 or 4 on the spot model at factories, and operations of medical representatives always comply with the guidelines of the Ministry of Health in order to protect health for all Imexpharm employees.
The Company is following closely the schedule to accredit EU-GMP for IMP4 and expects the plant would receive certification within the first 6 months of 2022.
Although restrictions are being eased, selling, support, and marketing activities have not been restarted yet because social distancing is still implemented in some provinces. Imexpharm continuously enhances online events to stimulate sales.
In addition, account receivables and inventories in the last months of the year have to be controlled tightly to gradually shorten the operating cycle of the Company.

Related post

New product

ATORVIS 20 thuốc hạ lipid

ATORVIS 20 thuốc hạ lipid Atorvastatin là thuốc hạ lipid máu thuộc nhóm statin - là...

Claminat® 625mg

Please contact us for more information! Amoxicillin là kháng sinh bán tổng hợp thuộc nhóm β...

PMS-MEXCOLD 650

Đang cập nhật

INTRODUCTION VIDEO